Abbott Laboratories (ABT) : Mufg Americas Holdings Corp reduced its stake in Abbott Laboratories by 3.85% during the most recent quarter end. The investment management company now holds a total of 306,383 shares of Abbott Laboratories which is valued at $13,802,554 after selling 12,260 shares in Abbott Laboratories , the firm said in a disclosure report filed with the SEC on Aug 8, 2016.Abbott Laboratories makes up approximately 0.47% of Mufg Americas Holdings Corp’s portfolio.
Other Hedge Funds, Including , Bnp Paribas Investment Partners S.a. reduced its stake in ABT by selling 55,429 shares or 27.57% in the most recent quarter. The Hedge Fund company now holds 145,607 shares of ABT which is valued at $6,559,595. Abbott Laboratories makes up approx 0.06% of Bnp Paribas Investment Partners S.a.’s portfolio.Bridgewater Wealth Financial Management reduced its stake in ABT by selling 637 shares or 0.49% in the most recent quarter. The Hedge Fund company now holds 128,888 shares of ABT which is valued at $5,793,516. Abbott Laboratories makes up approx 2.05% of Bridgewater Wealth Financial Management’s portfolio.Ngam Advisors reduced its stake in ABT by selling 99,651 shares or 26.98% in the most recent quarter. The Hedge Fund company now holds 269,755 shares of ABT which is valued at $12,125,487. Abbott Laboratories makes up approx 0.16% of Ngam Advisors’s portfolio.Fruth Investment Management reduced its stake in ABT by selling 100 shares or 0.24% in the most recent quarter. The Hedge Fund company now holds 41,275 shares of ABT which is valued at $1,732,312. Abbott Laboratories makes up approx 0.82% of Fruth Investment Management’s portfolio.Benin Management Corp boosted its stake in ABT in the latest quarter, The investment management firm added 52,460 additional shares and now holds a total of 78,728 shares of Abbott Laboratories which is valued at $3,304,214. Abbott Laboratories makes up approx 1.67% of Benin Management Corp’s portfolio.
Abbott Laboratories opened for trading at $45.2 and hit $45.23 on the upside on Monday, eventually ending the session at $45.15, with a gain of 0.24% or 0.11 points. The heightened volatility saw the trading volume jump to 65,25,830 shares. Company has a market cap of $66,370 M.
On the company’s financial health, Abbott Laboratories reported $0.55 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 20, 2016. Analyst had a consensus of $0.53. The company had revenue of $5333.00 million for the quarter, compared to analysts expectations of $5244.94 million. The company’s revenue was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.52 EPS.
Many Wall Street Analysts have commented on Abbott Laboratories. Abbott Laboratories was Upgraded by Edward Jones to ” Buy” on Jun 21, 2016.
Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.